Trabectedin (ET743; Ecteinascidin-743; ET-743; trade name Yondelis) is a novel antitumor agent of marine origin with potent in vitro and in vivo antitumour activity. As of 2015, it has been approved as an antitumor chemotherapy drug for the treatment of advanced soft-tissue sarcoma and ovarian cancer. Trabectedin induced cytotoxicity and apoptosis in both breast cancer cells in a time and concentration-dependent manner.

纯度：≥98%

CAS：114899-77-3